Review of the treatment of metastatic non small cell lung carcinoma: A practical approach

Table 2 Efficacy data in the second-line setting

Outcome	Erlotinib[41] (150 mg daily)	Docetaxel[38-40,46](75 mg/m2 , every 3 wk)	Pemetrexed[40] (500 mg/m2 , every 3 wk)
RR (%)	8.9	6.7-8.8	9.1
Median duration of response (mo)	7.9	5.3-9.1	4.6
Median PFS (mo)	2.2	2.7-6	2.9
Median OS (mo)	6.7	5.7-7.9	8.3
1-year survival (%)	31	30-37	30
2-year survival (%)	13	0	0
Median OS (mo) in PS 0/1 patients with one prior regimen	9.4	9.1	9.4

PFS: Progression-free survival; OS: Overall survival; PS: Performance status